Compare Mercadolibre Inc (MELI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs BIO-TECHNE Corp — how do they compare? Mercadolibre Inc trades at $1,864.18 (market cap $94.94B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Mercadolibre Inc is far larger — about 8.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and BIO-TECHNE Corp for 63 Days on average.
| MELI | TECH | |
|---|---|---|
Market Cap | $94.94B | $11.37B |
Volume | 428,337 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $72.61 |
52-Week Low | $1.55K | $43.31 |
Typical Hold Time | 117 Days | 63 Days |
Enterprise Value | $102.59B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,856.66, down slightly by 0.07% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported $28.89 billion in revenue for 2025, with net income of $2.00 billion, though profit margins have softened from 9.19% in 2024 to 6.91%. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy growth, while the fintech segment's credit portfolio surged 75% to $16.4 billion in Q2 2026.
The stock presents a growth opportunity with robust revenue expansion and dominant market position in Latin American e-commerce and fintech, but faces risks from macroeconomic pressures in key markets like Argentina and elevated valuation multiples. Analyst consensus is strongly bullish with a $2,170 price target, suggesting potential upside, though investors should weigh margin compression against ecosystem strength.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
